Semaglutide Patent Expiry and Its Impact on Weight Loss Drugs in India
Impact of Semaglutide Patent Expiry on Weight Loss Drugs
The semaglutide patent expiry on March 20, 2026, opens doors for numerous pharmaceutical companies to market generic semaglutide. As a result, significant price reductions, estimated at around 50%, for leading weight-loss therapeutics like Wegovy and Ozempic are anticipated.
Companies Preparing to Enter the Market
- Sun Pharma
- Zydus Lifesciences
- Dr. Reddy's Laboratories
- Natco Pharma
These firms aim to bring affordable obesity therapy to the forefront, enhancing patient access to effective treatments for conditions like obesity and type 2 diabetes. Such developments are vital for the expanding obesity drug market amid rising health concerns.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.